Literature DB >> 7633837

Neuroblastoma stage IV-S.

T D Miale1, K Kirpekar.   

Abstract

A review of stage IV-S neuroblastoma is provided. The possible uses of prognostic features to guide treatment options in this group of infants with neuroblastoma are suggested. The biologic basis for the spontaneous regression of widespread tumor involvement in some infants with stage IV-S neuroblastoma is discussed. The reasons that some infants with IV-S disease progress to a fatal outcome, while most undergo maturation or involution and eventual long term cure are suggested. The influence of such factors as age at diagnosis, clinical staging, and tumor biology on eventual outcome are covered. Biological variables and markers discussed include: genetic (cytogenetics (1p deletions), nuclear genomic content), molecular biologic (N-myc oncogene amplification, mdr-1, ras, and trk, gene expression), immunological (major histocompatibility antigen density, cellular and humoral immunity), and biochemical (creatine kinase isoenzyme profile, neuron specific enolase, ferritin, chromatograffin, lactic acid dehydrogenase and catecholamine levels).

Entities:  

Mesh:

Year:  1994        PMID: 7633837     DOI: 10.1007/bf02999856

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  68 in total

1.  Inhibition of growth factor-induced differentiation of PC12 cells by microinjection of antibody to ras p21.

Authors:  N Hagag; S Halegoua; M Viola
Journal:  Nature       Date:  1986 Feb 20-26       Impact factor: 49.962

Review 2.  Do children benefit from mass screening for neuroblastoma? Consensus Statement from the American Cancer Society Workshop on Neuroblastoma Screening.

Authors:  S B Murphy; S L Cohn; A W Craft; W G Woods; T Sawada; R P Castleberry; H L Levy; P C Prorok; G D Hammond
Journal:  Lancet       Date:  1991-02-09       Impact factor: 79.321

3.  A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene.

Authors:  E P Reddy; R K Reynolds; E Santos; M Barbacid
Journal:  Nature       Date:  1982-11-11       Impact factor: 49.962

Review 4.  Immunotherapy. Neuroblastoma as a model.

Authors:  N K Cheung
Journal:  Pediatr Clin North Am       Date:  1991-04       Impact factor: 3.278

5.  Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis.

Authors:  P Kogner; G Barbany; C Dominici; M A Castello; G Raschellá; H Persson
Journal:  Cancer Res       Date:  1993-05-01       Impact factor: 12.701

6.  Age-linked prognostic categorization based on a new histologic grading system of neuroblastomas. A clinicopathologic study of 211 cases from the Pediatric Oncology Group.

Authors:  V V Joshi; A B Cantor; G Altshuler; E W Larkin; J S Neill; J J Shuster; C T Holbrook; F A Hayes; R Nitschke; M H Duncan
Journal:  Cancer       Date:  1992-04-15       Impact factor: 6.860

Review 7.  Neuroblastoma: the result of multistep transformation?

Authors:  G P Tonini
Journal:  Stem Cells       Date:  1993-07       Impact factor: 6.277

8.  Neuroblastoma. Mass screening for early detection and its prognosis.

Authors:  T Sawada; T Kidowaki; I Sakamoto; T Hashida; T Matsumura; M Nakagawa; T Kusunoki
Journal:  Cancer       Date:  1984-06-15       Impact factor: 6.860

9.  Localized but unresectable neuroblastoma: treatment and outcome of 145 cases. Italian Cooperative Group for Neuroblastoma.

Authors:  A Garaventa; B De Bernardi; C Pianca; A Donfrancesco; L Cordero di Montezemolo; M T Di Tullio; S Bagnulo; A Mancini; M Carli; A Pession; A Arrighini; A Di Cataldo; P Tamaro; V Iasonni; A Taccone; D Rogers; L Boni
Journal:  J Clin Oncol       Date:  1993-09       Impact factor: 44.544

10.  The diagnostic and prognostic value of pretreatment serum creatine kinase BB levels in patients with neuroblastoma.

Authors:  Y Ishiguro; K Kato; H Akatsuka; T Ito
Journal:  Cancer       Date:  1990-05-01       Impact factor: 6.860

View more
  2 in total

Review 1.  Efficacy and toxicity of radiation in preparative regimens for pediatric stem cell transplantation. I: Clinical applications and therapeutic effects.

Authors:  T D Miale; S Sirithorn; S Ahmed
Journal:  Med Oncol       Date:  1995-12       Impact factor: 3.064

Review 2.  Efficacy and toxicity of radiation in preparative regimens for pediatric stem cell transplantation. II: Deleterious consequences.

Authors:  T D Miale; S Sirithorn; S Ahmed
Journal:  Med Oncol       Date:  1996-03       Impact factor: 3.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.